Findings

What do systematic reviews say?

1,187 questions · 1,233 findings · 137 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 190 · 15.4%GRADE not reported 57 · 4.6%Very low 241 · 19.5%Low 323 · 26.2%Moderate 315 · 25.5%High 107 · 8.7%

Intervention not reported

CFB in ACQ at 3 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 768(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 764(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 771(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 767(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 2079(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3 participants
Moderate

Intervention not reported

CFB in ACQ at 3 months ‐ TRIPLE vs DUAL№ of participants: 1535(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3762(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1961(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1952(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2561(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 3459(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Low

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 3288(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ TRIPLE vs DUAL№ of participants: 5408(4 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3152(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 12 participants
Low

Intervention not reported

Outcome№ of participants(studies)

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CFB in ACQ at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1366(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1379(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 1967(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Low

Intervention not reported

CFB in ACQ at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 2887(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 12 participants
Moderate